Related Experiment Video
Updated: Jun 24, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic
P Secchiero1, D Sblattero, C Chiaruttini
1Department of Morphology and Embryology, University of Ferrara, Italy. paola.secchiero@unife.it
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising natural anticancer therapeutic agent because through its death receptors, TRAIL-R1 and TRAIL-R2, it induces apoptosis in many transformed tumor cells, but not in the majority of normal cells. Hence, agonistic compounds directed against TRAIL death receptors have the potential of being excellent cancer therapeutic agents, with minimal cytotoxicity in normal tissues. Here, we report the selection and characterization of a new single-chain fragment variable (scFv) to TRAIL-R2 receptor isolated from a human phage-display library, produced as minibody (MB), and characterized for the in vitro anti-leukemic tumoricidal activity. The anti-TRAIL-R2 MB2.23 efficiently and specifically bound to membrane-associated TRAIL-R2 on different leukemic cell lines and could act as a direct agonist in vitro, initiating apoptotic signaling as well as complement-dependent cytotoxicity and antibody-dependent cell cytotoxicity, providing a rationale for further investigations of MB2.23 in anticancer therapy.
Insights
Researchers developed a novel minibody targeting TRAIL-R2 for cancer therapy. This agent effectively induces apoptosis in leukemia cells, showing promise for targeted anticancer treatments with reduced normal tissue toxicity.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells via TRAIL-R1 and TRAIL-R2.
- TRAIL-based therapies offer potential for targeted cancer treatment with minimal normal tissue damage.
- Developing agonistic compounds targeting TRAIL death receptors is a key strategy in cancer therapeutics.
Purpose of the Study:
- To select and characterize a novel single-chain fragment variable (scFv) minibody (MB) targeting TRAIL-R2.
- To evaluate the in vitro anti-leukemic tumoricidal activity of the developed MB.
- To assess the potential of MB2.23 as a direct agonist for inducing apoptosis in cancer cells.
Main Methods:
- Isolation of an anti-TRAIL-R2 scFv from a human phage-display library.
- Production of the scFv as a minibody (MB2.23).
- In vitro characterization of MB2.23 binding specificity and functional activity, including apoptosis induction, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ADCC).
Main Results:
- MB2.23 efficiently and specifically bound to membrane-associated TRAIL-R2 on various leukemic cell lines.
- MB2.23 acted as a direct agonist, initiating apoptotic signaling pathways.
- MB2.23 demonstrated both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Conclusions:
- MB2.23 is a potent and specific agonist of TRAIL-R2 with significant in vitro anti-leukemic activity.
- The observed induction of apoptosis, CDC, and ADCC supports the therapeutic potential of MB2.23.
- MB2.23 warrants further investigation as a novel therapeutic agent for anticancer therapy, particularly for leukemia.
More Related Videos
13:14Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
